SIONNA THERAPEUTICS INC
SION
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Sionna Therapeutics is a clinical-stage biotechnology company developing small molecule drugs for cystic fibrosis. Its drug development pipeline relies on animal testing as a required component of preclinical research and regulatory submissions to the FDA. The company’s lead programs, including its NBD1 inhibitors and other CFTR modulators, have progressed from animal models into Phase 1 and Phase 2 clinical trials. This standard industry practice of animal experimentation is central to its business model for bringing new pharmaceuticals to market.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.